Prof. Dr. Ali Osman Kaya

Education and Specialization

• 1993 — Istanbul University Faculty of Medicine
• 1998 — Cumhuriyet University, Internal Medicine residency
• 2008 — Gazi University, Medical Oncology fellowship
• 2011 — Associate Professor; 2017 — Professor

Clinical Interests

• Breast cancer
• Lung cancer
• Prostate cancer
• Gastrointestinal cancers
• Gynecologic cancers
• Immunotherapy
• Targeted and personalized treatments

Professional Experience

• 1994–1998 — Cumhuriyet University, Internal Medicine
• 1998–2000 — Erbaa State Hospital
• 2000–2003 — Tokat SSK Hospital
• 2003–2004 — Ankara SSK Ulus Hospital
• 2005–2008 — Gazi University, Medical Oncology fellowship
• 2008–2009 — Ankara Atatürk Training and Research Hospital
• 2009 — Rize University Training and Research Hospital
• 2009–2011 — Bakırköy Dr. Sadi Konuk Training and Research Hospital
• 2011–2020 and 2021–2025 — Medicana Beylikdüzü, Medical Oncology
• 2017 — Arel University; 2018–2020 — Biruni University, Internal Medicine
• 2020–2021 — Başakşehir Çam and Sakura City Hospital, Medical Oncology training supervisor
• From November 2025 — Medical Park Göztepe, Medical Oncology

Professional Memberships

• Turkish Society of Medical Oncology (TTOD)
• European Society for Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)

Verified Publication References

1. Tunbekici S, Sahin G, Ön S, Oruc A, Eryılmaz MK, Sakin A, Coskun A, Seyyar M, Uzundere FK, Kolemen E, Cabuk D, Efil SC, Demir T, Turkmen E, Ekinci F, Terzi A, Sahin TK, Guven DC, Aksoy S, Aytac A, Demirkıran Ö, Demir B, Culcuoglu I, Ersoy M, Asarkaya E, Camanlı U, Gezici B, Ozveren A, Sevınc A, Kitaplı S, Unlu A, Ozturk B, Turkel A, Dogan M, Aslan F, Yesilbas E, Kaplan E, Sakalar T, Sahin E, Emin G, Asık E, Yıldırım A, Guclu T, Ugurlu I, Kahvecioglu F, Hacıbekiroglu I, Tunbekici I, Bayram S, Kaya AO, Majidova N, Yalıcı O, Karateke M, Avcı N, Belen B, Bal H, Kınıkoglu O, Turkoz FP, Sımsek ET, Altınok O, Gunes TK, Altıntas YE, Guliyev M, Ozturk G, Erdem D, Duzkopru Y, Inal A, Guren AK, Yıldırım N, Telli TA, Danacı Y, Aydın U, Almuradova E, Yıldırım HC, Gursoy P, Sendur MAN, Goker E. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group. Int J Cancer. 2026 Apr 1;158(7):1881-1890. doi: 10.1002/ijc.70213. Epub 2025 Oct 28. PMID: 41147655.
2. Mildanoglu MM, Kutlu Y, Bas O, Koylu B, Dae SA, Sakin A, Erdem D, Sendur MAN, Tasci ES, Dane F, Kaya AO, Aykan MB, Ergun Y, Biter S, Dizdar O, Disel U, Selcukbiricik F, Kose F, Olmez OF, Demir G, Yalcin S, Bilici A. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study. Sci Rep. 2025 Jul 13;15(1):25336. doi: 10.1038/s41598-025-09707-3. PMID: 40653542.
3. Kutlu Y, Dae SA, Yilmaz F, Erdem D, Sendur MAN, Akbas S, Senocak Tasci E, Bas O, Dane F, Sakin A, Kaya AO, Aykan MB, Ergun Y, Biter S, Disel U, Korkmaz M, Selcukbiricik F, Kose F, Olmez OF, Bilici A, Demir G, Yalcin S. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study. Cancers (Basel). 2024 Jun 18;16(12):2251. doi: 10.3390/cancers16122251. PMID: 38927957.
4. Akyildiz A, Guven DC, Koksal B, Karaoglan BB, Kivrak D, Ismayilov R, Aslan F, Sutcuoglu O, Yazici O, Kadioglu A, Alan O, Majidova N, Erciyestepe M, Ozcan E, Akdag G, Taban H, Kaya AO, Guliyev M, Yildirim N, Sakalar T, Yazilitas D, Unal C, On S, Biter S, Demirci NS, Senler FC, Kemal Y, Halil OD, Gullu I, Aksoy S. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG). Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4991-4999. doi: 10.1007/s00405-024-08744-4. Epub 2024 May 25. PMID: 38795147.
5. Okuturlar Y, Gunaldi M, Tiken EE, Oztosun B, Inan YO, Ercan T, Tuna S, Kaya AO, Harmankaya O, Kumbasar A. Utility of peripheral blood parameters in predicting breast cancer risk. Asian Pac J Cancer Prev. 2015;16(6):2409-12. doi: 10.7314/apjcp.2015.16.6.2409. PMID: 25824773.
6. Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. Int J Clin Oncol. 2021 Aug;26(8):1506-1513. doi: 10.1007/s10147-021-01936-6. Epub 2021 May 23. PMID: 34023933.
7. Oruç Z, Kaplan MA, Karaağaç M, Özyurt N, Tatlı AM, Kaya AO, Menekşe S, Kut E, Koca S, Sever ÖN, Yasin İ, Ebinç S, Zeynelgil E, Sakin A, Turhal NS, Isikdogan A. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncol. 2021 May;17(13):1611-1624. doi: 10.2217/fon-2020-1032. Epub 2021 Feb 26. PMID: 33631986.
8. Erol C, Sendur MAN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, Erdem D, Kahraman S, Cakir E, Demirkiran A, On S, Dogan I, Erdogan AP, Koca S, Kubilay P, Eren OO, Cilbir E, Celik E, Araz M, Ozyukseler DT, Yildirim ME, Bahceci A, Taskaynatan H, Oyman A, Deniz GI, Menekse S, Kut E, Gulmez A, Sakin A, Nayir E, Acar R, Sen E, Inal A, Turhal S, Kaya AO, Paydas S, Tastekin D, Hacibekiroglu I, Cincin I, Bilici A, Mandel NM, Dede DS, Akinci MB, Oksuzoglu B, Uncu D, Yalcin B, Artac M. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21. PMID: 36510987.
9. Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. Eur Urol Focus. 2021 Sep;7(5):1061-1066. doi: 10.1016/j.euf.2020.09.010. Epub 2020 Sep 30. PMID: 33008789.
10. Bostan M, Bostan H, Kaya AO, Bilir O, Satiroglu O, Kazdal H, Karadag Z, Bozkurt E. Clinical events in mad honey poisoning: a single centre experience. Bull Environ Contam Toxicol. 2010 Jan;84(1):19-22. doi: 10.1007/s00128-009-9906-2. Epub 2009 Nov 25. PMID: 19937314.
11. Yaman E, Buyukberber S, Uner A, Coskun U, Yamac D, Ozturk B, Kaya AO, Yildiz R, Benekli M; Anatolian Society of Medical Oncology (ASMO). Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas. Tumori. 2008 Sep-Oct;94(5):674-80. doi: 10.1177/030089160809400505. PMID: 19112939.
12. Yaman E, Buyukberber S, Benekli M, Oner Y, Coskun U, Akmansu M, Ozturk B, Kaya AO, Uncu D, Yildiz R. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg. 2010 Oct;112(8):662-7. doi: 10.1016/j.clineuro.2010.05.003. Epub 2010 Jun 2. PMID: 20627551.
13. Yildiz R, Buyukberber S, Uner A, Yamac D, Coskun U, Kaya AO, Ozturk B, Yaman E, Benekli M. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest. 2010 Jan;28(1):33-7. doi: 10.3109/07357900802562996. PMID: 19995229.
14. Kaya AO, Kaya A, Gundogdu C. A case of lung nodular aspergilloma mimicking tumor metastasis accompanied by pulmonary embolism in a gastric cancer patient in remission. SAGE Open Med Case Rep. 2026 Jun 14;14:2050313X261454857. doi: 10.1177/2050313X261454857. eCollection 2026. PMID: 42305658.
15. Yaman E, Gonul II, Buyukberber S, Ozturk B, Akyurek N, Coskun U, Kaya AO, Yildiz R, Sare M, Kitapci M. Metastatic fibroblastic reticulum cell sarcoma of the liver: pathological and PET-CT evaluation. Pathology. 2009;41(3):289-92. doi: 10.1080/00313020902756329. PMID: 19291544.
16. Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, Alici S, Kaya AO, Yaman E, Ozturk B, Coskun U, Benekli M, Uncu D, Buyukberber S. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. J Oncol Pharm Pract. 2010 Sep;16(3):173-8. doi: 10.1177/1078155209347402. Epub 2009 Oct 15. PMID: 19833685.
17. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):683-6. PMID: 19256759.
18. Coskun U, Kaya AO, Buyukberber S, Benekli M, Uner A, Dikilitas M, Ozturk B, Yildiz R, Ozkan S, Yaman E, Yamac D. Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens. Med Oncol. 2008;25(2):133-6. doi: 10.1007/s12032-007-9005-3. Epub 2007 Sep 14. PMID: 18488154.
19. Alici S, Coskun U, Alkis N, Sevinc A, Dane F, Gumus M, Ozkan M, Kaya AO, Celenkoglu G, Buyukberber S, Altunbas M, Benekli M; Anatolian Society of Medical Oncology. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas. Asian Pac J Cancer Prev. 2009;10(6):1051-5. PMID: 20192582.
20. Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V, Coskun U, Yamac D, Sancak B, Uner A. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010 Oct;136(10):1471-6. doi: 10.1007/s00432-010-0803-1. Epub 2010 Feb 13. PMID: 20155284.
21. Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A; Anatolian Society of Medical Oncology (ASMO). Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Med Oncol. 2010 Mar;27(1):152-7. doi: 10.1007/s12032-009-9186-z. Epub 2009 Feb 26. PMID: 19242825.
22. Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S, Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society of Medical Oncology (ASMO). Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev. 2012;13(2):463-7. doi: 10.7314/apjcp.2012.13.2.463. PMID: 22524807.
23. Yaman E, Uner A, Er O, Coskun U, Buyukberber S, Dikilitas M, Polat M, Yamac D, Kaya AO, Yildiz R, Ozturk B, Benekli M. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med Oncol. 2007;24(4):431-5. doi: 10.1007/s12032-007-0035-7. PMID: 17917094.
24. Kaya AO, Buyukberber S, Coskun U, Yildiz R, Ozturk B, Yaman E, Adisen E, Gureli M, Benekli M. Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer. Cutan Ocul Toxicol. 2008;27(4):327-31. doi: 10.1080/15569520802431369. PMID: 18828046.
25. Yaman E, Coskun U, Ozturk B, Buyukberber S, Kaya AO, Coskun O, Buyukberber N, Yildiz R, Benekli M. Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. J Clin Neurosci. 2009 Apr;16(4):591-2. doi: 10.1016/j.jocn.2008.05.030. Epub 2009 Feb 6. PMID: 19201195.
26. Kaya AO, Buyukberber S, Dane F, Isikdogan A, Ustaalioglu BO, Coskun U, Yumuk PF, Dogu GG, Ozdemir NY, Sevinc A, Gumus M, Ozkan M, Yildiz R, Ozturk B, Yaman E, Benekli M; Anatolian Society of Medical Oncology. Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer. Tumori. 2010 May-Jun;96(3):400-4. doi: 10.1177/030089161009600304. PMID: 20845799.
27. Ozturk B, Buyukberber S, Coskun U, Yaman E, Yildiz R, Kaya AO, Oner Y, Benekli M. Solitary iris metastasis from breast cancer with dramatic course: case report. Med Oncol. 2007;24(4):463-5. doi: 10.1007/s12032-007-0019-7. PMID: 17917101.
28. Uner A, Ozturk B, Benekli M, Coskun U, Kocak S, Kaya AO, Unsal D, Erekul S, Yaman E, Yildiz R, Buyukberber S. Synchronize primary breast osteosarcoma and contralateral benign cystosarcoma phylloides: radiologic and pathologic imaging. Breast J. 2008 Jan-Feb;14(1):109-10. doi: 10.1111/j.1524-4741.2007.00533.x. PMID: 18186876.
29. Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. Oncol Lett. 2013 Aug;6(2):605-611. doi: 10.3892/ol.2013.1408. Epub 2013 Jun 17. PMID: 24137379.
30. Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Isıkdogan A, Alkis N, Buyukberber S, Yumuk F, Budakoglu B, Demirci U, Berk V, Bilici A, Inal A, Arpacı E, Benekli M; Anatolian Society of Medical Oncology (ASMO). The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. J Chemother. 2012 Aug;24(4):217-20. doi: 10.1179/1973947812Y.0000000020. PMID: 23040686.
31. Yaman E, Coskun U, Benekli M, Sozen S, Yamac D, Buyukberber S, Ozturk B, Kaya AO, Yildiz R, Tezel E. Coexistence of gastrointestinal stromal tumor (GIST) of the rectum and adenocarcinoma of the prostate in a patient with familial GIST. Onkologie. 2008 Dec;31(12):697-9. doi: 10.1159/000165070. Epub 2008 Nov 4. PMID: 19060509.
32. Yaman E, Buyukberber S, Uner A, Coskun U, Akmansu M, Benekli M, Yamac D, Ozturk B, Kaya AO, Yildiz R, Ozkan S, Gunel N. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Onkologie. 2008 Jun;31(6):309-13. doi: 10.1159/000127252. Epub 2008 May 27. PMID: 18547971.
33. Coşkun U, Kaya AO, Alkis N, Buyukberber S, Alici S, Celenkoglu G, Uncu D, Ozkan M, Sevinc A, Benekli M. UFT plus oral folinic acid with alternating oral and intravenous vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Onkologie. 2009 Oct;32(10):562-6. doi: 10.1159/000232314. Epub 2009 Sep 3. PMID: 19816072.
34. Kaya AO, Coskun U, Sancak B, Buyukberber S, Yildiz R, Gulbahar O, Benekli M, Ozenirler S. Increased serum granulocyte colony stimulating factor in Turkish hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):403-6. PMID: 19640182.
35. Yildiz R, Coskun U, Kaya AO, Ozturk B, Yaman E. Digital ischemic changes after gemcitabine therapy in a patient with metastatic non-small-cell lung cancer. Ann Pharmacother. 2007 May;41(5):901-2. doi: 10.1345/aph.1K055. Epub 2007 Apr 3. PMID: 17405819.
36. Yaman E, Ozturk B, Coskun U, Buyukberber S, Kaya AO, Yildiz R, Benekli M. Synchronous bilateral breast cancer in an aged male patient. Onkologie. 2010;33(5):255-8. doi: 10.1159/000305715. Epub 2010 Apr 21. PMID: 20502060.
37. Yildiz R, Coskun U, Kapucu O, Kaya AO, Akdemir UO, Benekli M, Buyukberber S. F-18 FDG uptake due to acinetobacter infection causing misinterpretation of treatment response in a lymphoma patient. Clin Nucl Med. 2007 Jun;32(6):471-3. doi: 10.1097/RLU.0b013e318053ed08. PMID: 17515759.
38. Bardakci M, Karakas H, Bayram D, Avci N, Kitapli S, Ozen M, Aslan F, Koseoglu C, Kadioglu A, Onur ID, Sakalar T, Buyuksimsek M, Alkan A, Ergun Y, Kaya AO, Bilgin B, Yalcin B. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment. Sci Rep. 2024 May 9;14(1):10632. doi: 10.1038/s41598-024-61562-w. PMID: 38724585.
39. Yaman E, Benekli M, Coskun U, Sezer K, Ozturk B, Kaya AO, Yildiz R, Uluoglu O, Buyukberber S. Intrasellar plasmacytoma: an unusual presentation of multiple myeloma. Acta Neurochir (Wien). 2008 Sep;150(9):921-4; discussion 924. doi: 10.1007/s00701-008-0012-8. Epub 2008 Aug 23. PMID: 18726062.
40. Coskun U, Buyukberber S, Yaman E, Uner A, Er O, Ozkan M, Dikilitas M, Oguz M, Yildiz R, B DY, Kaya AO, Benekli M. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma. 2008;55(1):65-70. PMID: 18190244.
41. Ozturk B, Buyukberber S, Akmansu M, Coskun U, Yamac D, Uner A, Yaman E, Yildiz R, Kaya AO, Bora H, Unsal D, Pak Y, Benekli M. The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma. Med Oncol. 2008;25(3):269-73. doi: 10.1007/s12032-007-9029-8. Epub 2007 Dec 15. PMID: 18080790.
42. Kaya AO, Gunel N, Benekli M, Akyurek N, Buyukberber S, Tatli H, Coskun U, Yildiz R, Yaman E, Ozturk B. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. J BUON. 2012 Oct-Dec;17(4):663-8. PMID: 23335522.
43. Yildiz R, Coskun U, Buyukberber S, Sancak B, Kaya AO, Gulbahar O, Benekli M. Serum granulocyte colony-stimulating factor levels in gliomas. J BUON. 2011 Jan-Mar;16(1):138-41. PMID: 21674865.
44. Yildiz R, Benekli M, Akyurek N, Coskun U, Kaya AO, Ozturk B, Yaman E, Buyukberber S. Non-gestational uterine choriocarcinoma in a postmenopausal woman. Onkologie. 2009 Jul;32(7):417-9. doi: 10.1159/000219386. Epub 2009 Jun 19. PMID: 19556820.
45. Ozturk B, Tacoy G, Coskun U, Yaman E, Sahin G, Buyukberber S, Yildiz R, Kaya AO, Topal S, Ozdemir M, Benekli M. Gemcitabine-induced acute coronary syndrome: a case report. Med Princ Pract. 2009;18(1):76-80. doi: 10.1159/000163051. Epub 2008 Dec 4. PMID: 19060498.
46. Kaya AO, Coskun U, Ozkan M, Sevinc A, Yilmaz AU, Gumus M, Unal OU, Ozdemir NY, Alici S, Berk V, Degerli H, Oner MK, Ozturk C, Kefeli U, Camcı C; Anatolian Society of Medical Oncology (ASMO). Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy. Onkologie. 2012;35(10):576-80. doi: 10.1159/000342674. Epub 2012 Sep 18. PMID: 23038228.
47. Yaman E, Benekli M, Coskun U, Ozturk B, Kaya AO, Yildiz R, Buyukberber S. Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171). Ann Oncol. 2008 Feb;19(2):397-8; author reply 398. doi: 10.1093/annonc/mdm577. PMID: 18260185.
48. Kaya AO, Coskun U, Buyukberber S, Benekli M, Tekin E, Cifter C, Ozturk B, Yildiz R, Yaman E, Uner A, Yamac D. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer. J BUON. 2010 Apr-Jun;15(2):248-54. PMID: 20658717.
49. Kaya AO, Orhun-Yavuz HS, Ucgul E, Kurt A. Primary malignant melanoma of the rectum presenting with lower gastrointestinal bleeding. J BUON. 2011 Jul-Sep;16(3):570. PMID: 22006771.
50. Kaya AO, Coskun U, Yildiz R, Gonul II, Karagulle K, Yaman E, Ozturk B. Primary pure small cell carcinoma of the urinary bladder that responded to carboplatin plus etoposide: a case report and review of the literature. J BUON. 2009 Oct-Dec;14(4):703-6. PMID: 20148466.